Literature DB >> 14727923

Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.

Zhongwen Wang1, Jin Zhou, Xiufen Lu, Zhilong Gong, X Chris Le.   

Abstract

Arsenic has been used successfully in clinical trials for treating acute promyelocytic leukemia (APL). Although sublethal doses of inorganic arsenic are used, little is known about the pharmacokinetics and metabolism of the high levels of arsenic in APL patients. To fill this important gap, this study describes the speciation of arsenic in urine from four APL patients treated with arsenic. Each patient was injected daily with an arsenite (As(III)) solution that contained 10 mg of As(2)O(3) precursor. Speciation analysis of the patient urine samples collected consecutively for 48 h, encompassing two intravenous injections of arsenic, revealed the presence of monomethylarsonous acid (MMA(III)), dimethylarsinous acid (DMA(III)), monomethylarsonic acid (MMA(V)), and dimethylarsinic acid (DMA(V)). The intermediate methyl arsenic metabolites, MMA(III) and DMA(III), were detected in most urine samples from all of the patients when a preservative, diethyldithiocarbomate, was added to the urine samples to stabilize these trivalent arsenic species. The major arsenic species detected in the urine samples from the patients were As(III), MMA(V), and DMA(V), accounting for >95% of the total arsenic excreted. The relative proportions of As(III), As(V), MMA(V), and DMA(V) in urine samples collected 24 h after the injections of As(III) were 27.6 +/- 6.1, 2.8 +/- 2.0, 22.8 +/- 8.1, and 43.7 +/- 13.3%, respectively. The relatively lower fraction of the methylated arsenic species in these APL patients under arsenic treatment as compared with that from the general population exposed to much lower levels of arsenic suggests that the high levels of As(III) inhibit the methylation of arsenic (inhibits the formation of methyl arsenic metabolites). The arsenic species excreted into the urine accounted for 32-65% of the total arsenic injected. These results suggest that other pathways of excretion, such as through the bile, may play an important role in eliminating (removing) arsenic from the human body when challenged by high levels of As(III).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727923     DOI: 10.1021/tx0341714

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  23 in total

1.  Using mathematical modeling to infer the valence state of arsenicals in tissues: A PBPK model for dimethylarsinic acid (DMAV) and dimethylarsinous acid (DMAIII) in mice.

Authors:  Lydia M Bilinsky; David J Thomas; Jeffrey W Fisher
Journal:  J Theor Biol       Date:  2018-10-26       Impact factor: 2.691

2.  Volatile arsenic species released from Escherichia coli expressing the AsIII S-adenosylmethionine methyltransferase gene.

Authors:  Chungang Yuan; Xiufen Lu; Jie Qin; Barry P Rosen; X Chris Le
Journal:  Environ Sci Technol       Date:  2008-05-01       Impact factor: 9.028

Review 3.  Arsenic trioxide - An old drug rediscovered.

Authors:  Ashkan Emadi; Steven D Gore
Journal:  Blood Rev       Date:  2010-05-15       Impact factor: 8.250

4.  Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.

Authors:  Haimei Chen; Richard Ahn; Jeroen Van den Bossche; David H Thompson; Thomas V O'Halloran
Journal:  Mol Cancer Ther       Date:  2009-06-30       Impact factor: 6.261

5.  Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215).

Authors:  T Sakurai; C Kojima; Y Kobayashi; S Hirano; M H Sakurai; M P Waalkes; S Himeno
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

6.  Occurrence of trivalent monomethyl arsenic and other urinary arsenic species in a highly exposed juvenile population in Bangladesh.

Authors:  David A Kalman; Russell L Dills; Craig Steinmaus; Md Yunus; Al Fazal Khan; Md Mofijuddin Prodhan; Yan Yuan; Allan H Smith
Journal:  J Expo Sci Environ Epidemiol       Date:  2013-04-03       Impact factor: 5.563

Review 7.  Arsenic trioxide: insights into its evolution to an anticancer agent.

Authors:  Maneka Hoonjan; Vaibhav Jadhav; Purvi Bhatt
Journal:  J Biol Inorg Chem       Date:  2018-02-02       Impact factor: 3.358

8.  Speciation, formation, stability and analytical challenges of human arsenic metabolites.

Authors:  Lucy Yehiayan; Mahesh Pattabiraman; Konstantinos Kavallieratos; Xiaotang Wang; Lawrence H Boise; Yong Cai
Journal:  J Anal At Spectrom       Date:  2009-07-21       Impact factor: 4.023

9.  Comparative oxidation state specific analysis of arsenic species by high-performance liquid chromatography-inductively coupled plasma-mass spectrometry and hydride generation-cryotrapping-atomic absorption spectrometry.

Authors:  Jenna Currier; R Jesse Saunders; Lan Ding; Wanda Bodnar; Peter Cable; Tomáš Matoušek; John T Creed; Miroslav Stýblo
Journal:  J Anal At Spectrom       Date:  2013-06-01       Impact factor: 4.023

10.  Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry.

Authors:  Szabina Stice; Guangliang Liu; Shannon Matulis; Lawrence H Boise; Yong Cai
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-12-08       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.